Paper30177832
Heterogeneous cancer-associated fibroblast population potentiates neuroendocrine differentiation and castrate resistance in a CD105-dependent manner.
Kato M and 14 others. Oncogene, 2019. Cited by 77 papers, by iCite.
Cite this record
ConductScience Library. Heterogeneous cancer-associated fibroblast population potentiates neuroendocrine differentiation and castrate resistance in a CD105-dependent manner. Papers, record 30177832. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30177832
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cell Differentiation | Major topic |
| Endoglin | Major topic |
| Fibroblasts | Major topic |
| Neoplasm Proteins | Major topic |
| Neuroendocrine Cells | Major topic |
| Prostatic Neoplasms, Castration-Resistant | Major topic |
| Signal Transduction | Major topic |
| Cell Line, Tumor | |
| Humans | |
| Male |
Source PubMed
Grants9
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| T32 DK007770 | NIDDK NIH HHS | United States | T32DK007770 | PubMed and NIH | NIH RePORTER |
| CA108646 | U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) | International | R01CA108646 | PubMed and NIH | NIH RePORTER |
| P01 CA098912 | NCI NIH HHS | United States | P01CA098912 | PubMed and NIH | NIH RePORTER |
| BX001040 | U.S. Department of Veterans Affairs (VA) | International | I01BX001040 | PubMed and NIH | NIH RePORTER |
| PC160946 | U.S. Department of Defense (DOD) | International | PubMed | PubMed | |
| CA098912 | U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) | International | P01CA098912 | PubMed and NIH | NIH RePORTER |
| R01 CA108646 | NCI NIH HHS | United States | R01CA108646 | PubMed and NIH | NIH RePORTER |
| I01 BX001040 | BLRD VA | United States | I01BX001040 | PubMed and NIH | NIH RePORTER |
| PC161016 | U.S. Department of Defense (DOD) | International | PubMed | PubMed |
References48
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27207661 | Icaritin suppresses development of neuroendocrine differentiation of prostate cancer through inhibition of IL-6/STAT3 and Aurora kinase A pathways in TRAMP mice. | Carcinogenesis | 2016 | https://conductscience.org/library/papers/27207661 | PubMed |
| 2 | 25956356 | Zodiac: A Comprehensive Depiction of Genetic Interactions in Cancer by Integrating TCGA Data. | J Natl Cancer Inst | 2015 | https://conductscience.org/library/papers/25956356 | PubMed |
| 3 | 28740046 | INITIAL EXPERIENCE OF THE ENZALUTAMIDE TREATMENT FOR CASTRATION-RESISTANT PROSTATE CANCER. | Nihon Hinyokika Gakkai Zasshi | 2016 | https://conductscience.org/library/papers/28740046 | PubMed |
| 4 | 25307287 | Pathological significance and prognostic role of microvessel density, evaluated using CD31, CD34, and CD105 in prostate cancer patients after radical prostatectomy with neoadjuvant therapy. | Prostate | 2015 | https://conductscience.org/library/papers/25307287 | PubMed |
| 5 | 24881730 | Enzalutamide in metastatic prostate cancer before chemotherapy. | N Engl J Med | 2014 | https://conductscience.org/library/papers/24881730 | PubMed |
| 6 | 18371946 | Secreted frizzled related protein 1 is a paracrine modulator of epithelial branching morphogenesis, proliferation, and secretory gene expression in the prostate. | Dev Biol | 2008 | https://conductscience.org/library/papers/18371946 | PubMed |
| 7 | 21673995 | The role of calcineurin/NFAT in SFRP2 induced angiogenesis--a rationale for breast cancer treatment with the calcineurin inhibitor tacrolimus. | PLoS One | 2011 | https://conductscience.org/library/papers/21673995 | PubMed |
| 8 | 25407442 | A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer. | BJU Int | 2015 | https://conductscience.org/library/papers/25407442 | PubMed |
| 9 | 23518348 | The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. | Cancer Cell | 2013 | https://conductscience.org/library/papers/23518348 | PubMed |
| 10 | 28905415 | Hyperactive mTOR induces neuroendocrine differentiation in prostate cancer cell with concurrent up-regulation of IRF1. | Prostate | 2017 | https://conductscience.org/library/papers/28905415 | PubMed |
| 11 | 23826159 | Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. | PLoS One | 2013 | https://conductscience.org/library/papers/23826159 | PubMed |
| 12 | 16288033 | Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer. | Cancer Res | 2005 | https://conductscience.org/library/papers/16288033 | PubMed |
| 13 | 23728425 | The perivascular niche regulates breast tumour dormancy. | Nat Cell Biol | 2013 | https://conductscience.org/library/papers/23728425 | PubMed |
| 14 | 21863023 | Upregulation of cancer-associated myofibroblasts by TGF-β from scirrhous gastric carcinoma cells. | Br J Cancer | 2011 | https://conductscience.org/library/papers/21863023 | PubMed |
| 15 | 28620903 | Emerging Categories of Disease in Advanced Prostate Cancer and Their Therapeutic Implications. | Oncology (Williston Park) | 2017 | https://conductscience.org/library/papers/28620903 | PubMed |
| 16 | 29112233 | Neuroendocrine tumors and fibrosis: An unsolved mystery? | Cancer | 2017 | https://conductscience.org/library/papers/29112233 | PubMed |
| 17 | 1712249 | Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. | Cancer Res | 1991 | https://conductscience.org/library/papers/1712249 | PubMed |
| 18 | 25719802 | Diagnostic value of SFRP1 as a favorable predictive and prognostic biomarker in patients with prostate cancer. | PLoS One | 2015 | https://conductscience.org/library/papers/25719802 | PubMed |
| 19 | 16258976 | The molecular genetics of gastroenteropancreatic neuroendocrine tumors. | Cancer | 2005 | https://conductscience.org/library/papers/16258976 | PubMed |
| 20 | 27487144 | Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. | Oncotarget | 2016 | https://conductscience.org/library/papers/27487144 | PubMed |
Cited by68
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 77 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42694990 | The Role of Distinct Cancer-Associated Fibroblast Subtypes in Prostate Cancer Immunotherapy. | Int J Biol Sci | 2026 | https://conductscience.org/library/papers/42694990 | PubMed |
| 42518286 | Local growth hormone promotes benign prostatic hyperplasia. | JCI Insight | 2026 | https://conductscience.org/library/papers/42518286 | PubMed |
| 42276991 | CAF-derived PTGDS drives pancreatic cancer neuroendocrine differentiation and chemoresistance via PAQR9-MAPK. | Oncogenesis | 2026 | https://conductscience.org/library/papers/42276991 | PubMed |
| 41689691 | Neuroendocrine prostate cancer (NEPC) in focus: state of the art and future prospectives. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41689691 | PubMed |
| 41378308 | Optimised dissociation and multimodal profiling of prostate cancer stroma reveal fibromuscular cell heterogeneity with clinical correlates. | Front Cell Dev Biol | 2025 | https://conductscience.org/library/papers/41378308 | PubMed |
| 41327620 | A Metastasis-competent CAF Subpopulation Defined by MFAP5⁺THY1⁺ Co-expression Drives Prostate Cancer Metastasis via EMT Activation. | Recent Pat Anticancer Drug Discov | 2026 | https://conductscience.org/library/papers/41327620 | PubMed |
| 41327318 | Unraveling the YAP1-TGFβ1 axis: a key driver of androgen receptor loss in prostate cancer-associated fibroblasts. | J Exp Clin Cancer Res | 2025 | https://conductscience.org/library/papers/41327318 | PubMed |
| 41136557 | Cytokine CCL2 secreted by cancer-associated fibroblasts augments temozolomide resistance in glioblastoma through ERK1/2 signaling. | Oncogene | 2025 | https://conductscience.org/library/papers/41136557 | PubMed |
| 40917018 | Enzalutamide-Resistant STEAP4+ MyoCAF Secrete Phosphatidylcholine to Foster Progression by Activating Stemness in Hormone-Sensitive Prostate Cancer. | Adv Sci (Weinh) | 2025 | https://conductscience.org/library/papers/40917018 | PubMed |
| 40644310 | Endoglin mediates the tumor- and metastasis-promoting traits of stromal myofibroblasts in human breast carcinomas. | Mol Oncol | 2025 | https://conductscience.org/library/papers/40644310 | PubMed |
| 40499539 | CXCR4-LASP1-G9a-SNAIL axis drives NEPC transdifferentiation via induction of EMT and downregulation of REST. | Cell Genom | 2025 | https://conductscience.org/library/papers/40499539 | PubMed |
| 40375322 | CD105+ fibroblasts support an immunosuppressive niche in women at high risk of breast cancer initiation. | Breast Cancer Res | 2025 | https://conductscience.org/library/papers/40375322 | PubMed |
| 40293223 | A Cyanobacteria-Derived RNA Aptamer Resensitizes Prostate Cancer to Hormone Therapy. | Cancer Res | 2025 | https://conductscience.org/library/papers/40293223 | PubMed |
| 40097577 | The fibroinflammatory response in cancer. | Nat Rev Cancer | 2025 | https://conductscience.org/library/papers/40097577 | PubMed |
| 39335188 | Evidence of the Link between Stroma Remodeling and Prostate Cancer Prognosis. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39335188 | PubMed |
| 39300373 | SFRP1 mediates cancer-associated fibroblasts to suppress cancer cell proliferation and migration in head and neck squamous cell carcinoma. | BMC Cancer | 2024 | https://conductscience.org/library/papers/39300373 | PubMed |
| 38708176 | Evolving Tumor Characteristics and Smart Nanodrugs for Tumor Immunotherapy. | Int J Nanomedicine | 2024 | https://conductscience.org/library/papers/38708176 | PubMed |
| 38335292 | Stromal-derived MAOB promotes prostate cancer growth and progression. | Sci Adv | 2024 | https://conductscience.org/library/papers/38335292 | PubMed |
| 38078010 | Poly I:C-priming of adipose-derived mesenchymal stromal cells promotes a pro-tumorigenic phenotype in an immunocompetent mouse model of prostate cancer. | Front Cell Dev Biol | 2023 | https://conductscience.org/library/papers/38078010 | PubMed |
| 38070051 | Single-cell analysis extracted CAFs-related genes to established online app to predict clinical outcome and radiotherapy prognosis of prostate cancer. | Clin Transl Oncol | 2024 | https://conductscience.org/library/papers/38070051 | PubMed |
Genes39
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30177832
GET https://conductscience.org/api/papers/v1/30177832/references?page=2